Contents

Search


piperacillin (Pipracil)

Tradename: Pipracil. 4th generation penicillin. Indications: - treatment of serious bacterial infections cause by susceptible gram-negative organisms: - infectious arthritis, osteomyelitis - skin or soft tissue infection - urogenital infection - gonorrhea - urinary tract infection - lower respiratory tract infection - intra-abdominal infection - bacteremia - indicated for infections caused by Pseudomonas aeruginosa & Enterobacteriaceae - use in combination with an aminoglycoside or quinolone - prophylaxis for perioperative infection - gastrointestinal surgery - cesarean section - hysterectomy [6] Dosage: 1) 3-4 g IV every 4-6 hours 2) 2-3 g IM every 6-12 hours Powder for injection: 2 g, 3 g, 4 g. Dosage adjustment in renal failure: Creatinine clearance mild-moderate infection serious infection > 40 mL/min 3-4 g IV every 8 hours 3-4 g IV every 6 hours 20-39 mL/min* 3-4 g IV every 12 hours 3-4 g IV every 8 hours < 19 mL/min# 3 g IV every 12 hours 3-4 g IV every 12 hours * same dose for continuous arteriovenous hemofiltration # dose after hemodialysis Pharmacokinetics: 1) 70-80% of an IM dose is absorbed 2) well distributed to most body tissues & fluids a) pleural, peritonal, synovial & wound fluids b) sputum & bone c) minimal CSF penetration unless meninges are inflamed; therapeutic concentrations in the CNS may be obtained with inflammed meninges d) crosses placenta e) distributes into milk at low concentrations 3) time to peak concentration 30-50 minutes 4) protein-binding 22% 5) elimination 1/2life is 1 hour (3.3-5 hours ESRD) 6) eliminated primarily by the kidney (70%) 7) 10-30% eliminated in the bile 8) dosage adjustment necessary with renal insufficiency 9) 20-50% dializable Antimicrobial activity: Gram positive - Streptococcus - Streptococcus group A - Streptococcus group B - Streptococcus group C - Streptococcus group G - Streptococcus pneumonia - Streptococcus viridans, milleri - Enterococcus faecalis (+/-) - Enterococcus faecium (+/-) - Listeria monocytogenes Gram negative - Neisseria gonorrhoeae - Neisseria meningitidis - Moraxella catarrhalis (+/-) - Haemophilus influenzae (+/-) - Escherichia coli - Klebsiella species - Enterobacter species - Salmonella species - Shigella species - Proteus mirabilis - Proteus vulgaris - Providencia species - Morganella species - Citrobacter species - Aeromonas species - Pseudomonas aeruginosa - Xanthomonas maltophilia - Yersinia enterocolitica - Pasteurella multocida - Acinetobacter [6] Anaerobes - Actinomyces - Bacteroides fragilis - Bacteroides melaninogenicus - Clostridium difficile - Clostridium species - Peptostreptococcus species Adverse effects: 1) uncommon (< 1%) - thrombophlebitis, convulsions, confusion, drowsiness, fever, rash, electrolyte imbalance, hemolytic anemia, positive direct antiglobulin test (Coomb's test, DAT), myoclonus, acute interstitial nephritis*, Jarisch-Herxheimer reaction, hypersensitivity reactions, anaphylaxis, abnormal platelet aggregation, prolonged prothrombin time (high doses) 2) other - diarrhea - rare blood dyscrasias - increased serum transaminases - increased BUN & creatinine - seizures (rare) * generally complete recovery of renal function (may take months) if piperacillin discontinued immediately after onset of acute kidney injury [7] Drug interactions: 1) probenecid increased concentration & prolongs 1/2life of piperacillin 2) aminoglycosides are inactivated by piperacillin when mixed in same IV bag Laboratory: - piperacillin in serum/plasma Mechanism of action: inhibition of bacterial cell wall synthesis

Interactions

drug interactions

General

4th generation penicillin (extended-spectrum)

Properties

MISC-INFO: elimination route KIDNEY pregnancy-category B safety in lactation ? protein-binding 22% elimination by hemodialysis +/-

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Harrison's Principles of Internal Medicine, 13th ed. Companion Handbook. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1995, pg 161
  3. Sanford Guide to antimicrobial therapy 1997
  4. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  5. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  6. Deprecated Reference
  7. Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022

Component-of

piperacillin tazobactam (Zosyn)